Chembio Wins $13.2M US BARDA Contract To Develop POC Zika Tests

HHS and its subagency Biomedical Advanced Research and Development Authority (BARDA) has put together additional funding to award Chembio Diagnostic Systems $13.2m to develop and commercialize the firm's rapid point-of-care Zika test, a mere two weeks after the agency said it only had enough funds for Zika vaccine development.

Chembio Diagnostics Inc. announced on Aug. 25 a fresh, $13.2m total contract from BARDA, HHS's Biomedical Advanced Research and Development Authority, so it can carry out development and commercialization of its rapid point-of-care Zika test, although in mid-August HHS Secretary Sylvia Burwell was concerned about finding an additional $342m to support diagnostics development to help pinpoint suspected cases in the US. (Also see "Hologic Wins $4.1m To Advance Zika Blood Screen" - Medtech Insight, 15 August, 2016.)

Chembio plans to use an initial $5.9m allotment from BARDA to work on its DPP Zika IgM/IgG Assay and DPP...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

Dermal Fillers For Décolletage May Gain FDA Approval

 
• By 

An upcoming US FDA advisory panel meeting will discuss adding a new indication to allow dermal fillers to be used in the upper chest, or décolletage. Plastic surgeons expect this could drive interest in the procedure, which is already performed off-label.

Court Orders US FDA To Return Trial Diversity Action Plan Guidance To Website

 
• By 

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.

Planning To Take Part in MDUFA? FDA Wants To Hear From You

 

The US FDA needs to know who wants a seat at the MDUFA negotiations table before discussions can begin. The agency is asking stakeholders to let it know if they plan to participate in the periodic consultation meetings before July 28.

Investors Urged To Prioritize Patient Engagement To Ensure Clients’ Products Succeed

 

To succeed in medtech, investors must focus on patient outcomes. Gilde Healthcare says involving patients boosts product effectiveness, access and market success — making it a smart strategy in today’s strained healthcare systems.

More from North America